CAMBRIDGE, Mass. — Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, announced that it has appointed Susan Keefe as its Chief Financial Officer. Keefe brings a 30-year background in finance, accounting, and operations within the life sciences sector and most recently served as the company’s acting CFO through her role at Quotient’s founder, Flagship Pioneering.
“Susan brings a powerful combination of strategic insight, operational rigor and experience building and scaling public and private life science organizations,” said Rahul Kakkar, MD, president and chief executive officer of Quotient. “We are thrilled to have her join Quotient as we continue to leverage somatic genomics to build our internal and partnered portfolio.”
Keefe said she is eager to support the company’s next phase of growth. “Somatic genomics has the potential to uncover novel biological insights that inform breakthrough therapies across a broad range of diseases. I look forward to joining the Quotient team and building a solid financial and operational foundation to support the Company’s long-term growth and value creation strategy,” she said.
Before joining Flagship Pioneering, Keefe served as interim chief financial officer of Benson Hill. She previously held the CFO role at GreenLight Biosciences, where she guided financial strategy for a company developing RNA-based solutions spanning agriculture and human health. Earlier in her career, she held senior finance and administrative roles at Danforth Advisors and Aushon Biosystems, and worked at SeraCare Life Sciences, Procter & Gamble, and PwC.
Keefe holds an MBA in strategic management, finance, marketing, and entrepreneurship from the University of Chicago Booth School of Business, as well as a BBA in accounting from the University of Iowa.
